Abstract
HBM4003 is a fully human heavy chain only monoclonal antibody targeting CTLA-4. In addition to blocking the CTLA-4 pathway, HBM4003 is also engineered to deplete Treg cells by enhanced antibody-dependent cellular cytotoxicity (ADCC) activity that was clinically validated. Here we reported updated results of a phase I study that evaluated HBM4003 plus toripalimab (anti-PD-1 antibody) in advanced melanoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
